scholarly journals Bochdalek Hernia and Partial Diaphragmatic Agenesis: Pedicled Intercostal Muscle Flap and Mesh Repair in a Young Adult with Sickle Cell Disease

2021 ◽  
Vol 07 (04) ◽  
pp. e363-e365
Author(s):  
Klein Dantis ◽  
Devendra Kumar Rathore ◽  
Nilesh Gupta ◽  
Subrata Kumar Singha

AbstractCongenital Bochdalek hernia (BH) in an adult is rare and has an unusual presentation. They are confined to the pediatric age group with an incidence of 1:3,000 live births. It rarely persists asymptomatic until adulthood. Surgical repair by thoracic, abdominal, or thoraco-abdominal approach is the treatment of choice with diaphragmatic reconstruction in associated diaphragmatic agenesis. With only 10 cases of BH with partial diaphragmatic agenesis reported to date, we discuss the rarity, unusual presentation, and management of BH in a young adult with sickle cell disease that has not been reported in the literature.

2021 ◽  
Vol 86 ◽  
pp. 102508
Author(s):  
Melissa Azul ◽  
Surbhi Shah ◽  
Sarah Williams ◽  
Gregory M. Vercellotti ◽  
Alexander A. Boucher

2013 ◽  
Vol 13 (1) ◽  
Author(s):  
AA Bokolombe ◽  
F Samato ◽  
T Lukinu ◽  
MB Ekila ◽  
MN Aloni

2008 ◽  
Vol 100 (3) ◽  
pp. 339-341 ◽  
Author(s):  
Rahul N. Julka ◽  
Farshad Aduli ◽  
Laura W. Lamps ◽  
Kevin W. Olden

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3414-3414
Author(s):  
Susan P. Perrine ◽  
Oluwakemi Owoyemi ◽  
Elizabeth S Klings ◽  
Mehdi Nouraie ◽  
Angela Rock ◽  
...  

Abstract Sleep disordered breathing including transient hypoxemia and hypercarbia are reported in 60-80% of adolescents and children with sickle cell disease (SCD); oxygen desaturation <93% is associated with exercise intolerance. Longer duration of oxygen desaturation, lower nadirs of oxygenation, and end-tidal carbon dioxide levels >50 mm Hg during sleep are associated with increased frequency of acute vaso-occlusion events and are suspected of contributing to microvasculature alterations. To assess the prevalence and degree of sleep-related hypoxemia and potential associations with cardiovascular functions in young adults with SCD, we performed overnight sleep studies using a Type II sleep monitor NOX-T3 (Carefusion, Inc), 6-minute walk tests, echocardiograms, hematologic and chemistry panels, and PSQI questionnaires in 17 adults with SCD, ages 21-30 years. Subjects were attending a sickle cell clinic solely for routine care with no expressed complaints of SDB. Exclusion criteria included acute clinical events, hospitalizations, or red cell transfusions within 4 weeks, and chronic transfusions. AHI>5 (significant apnea/hypopnea hypoxemic episodes) during sleep occurred in 7/17 (41%) of subjects, and these subjects had a higher median number of hypopneas (34 vs 12, p=0.005), and oxygen desaturation indices (ODI, 5.9 vs 2.0, p<0.001) than occurred in subjects with AHI scores ≤5, with a trend to lower oxygen saturation during sleep (lowest saturation of 78% vs 88%, P = 0.1). Patient-reported symptoms of SDB on the PSQI questionnaire were strongly associated with nocturnal hypoxemia (Sensitivity = 86%). All subjects had 6-minute walk distances below normal for healthy subjects, (mean 384 vs normal adult 876 meters). Left ventricular diastolic function was more affected in patients with AHI>5 (median MV EA ratio of 2.0 vs. 1.5, p = 0.08). TR jet velocity >2.5 was found in 2/17 asymptomatic subjects; (both were in the AHI>5 group). General quality of life was lower in patients with AHI>5 (mean score of 38 vs. 48, p = 0.012). As prolonged and frequent hypoxemic episodes may increase risks for vaso-occlusive, cardiovascular, and neurologic events, these common findings of significant nocturnal hypoxemia in young adult sickle cell subjects strongly suggest that SDB should be investigated further in larger patient populations, and interventions initiated. The observations, in addition to prior reports, also strongly suggest that screening of young adult SCD patients for SDB should be performed on a routine basis. Research reported in this publication was supported by the NHLBI under Award Number P50HL118006. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Disclosures Klings: Actelion Pharmaceuticals: Research Funding; Pfizer: Consultancy.


2007 ◽  
Vol 20 (2) ◽  
pp. S129-S130
Author(s):  
Teresa M. Erb ◽  
Kelly Gerschultz ◽  
Melanie A. Gold ◽  
Joseph S. Sanfilippo

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2383-2383
Author(s):  
Aravind Thavamani ◽  
Regi Ramanathan ◽  
Mammen Puliyel

Abstract Background: Sickle cell disease (SCD) is a life-threatening disease with varied clinical spectrum and severity leading to premature death. There is a lack of validated prognostic markers in SCD. Recent evidence suggests that inflammation and platelet adhesion plays a critical role in the pathophysiology of vaso-occlusion in SCD. Elevated Mean Platelet Volume (MPV) values are associated with a higher degree of inflammation in many disease states but its effect on sickle cell disease or its severity is unknown. Objective: To analyze the role of MPV in predicting disease severity/mortality in patients with SCD. Methodology: This is a retrospective single center study and included patients with sickle cell disease between 6 months and 60 years of age during a 10-year period (2006-2016). Demographic information, lab data and clinical information including acute chest syndrome (ACS), priapism, transfusions, sepsis, pain crisis, avascular necrosis (AVN) were collected. All laboratory data were collected in steady state with no crisis in the recent past 3 months. The disease severity score/probability of death was calculated using a validated model to predict risk of death in sickle cell disease (Sebastiani et al. Blood 2007). Spearman's correlation test was used to analyze correlation coefficient between MPV and probability of death. Results: Total no. of patients =230; Male 112 (49%); Female 118 (51%). All patients were of African-American origin. Disease severity, Hb SS - 156 (67.5%); Hb SC - 64 (27.8%) and Sickle-Beta thalassemia 11 (4.7%). MPV has a significant positive correlation with the probability of death, p < 0.001 and correlation coefficient, r=0.222. Of the total population, 78 had acute chest syndrome, 30 had AVN, 47 had recurrent pain crisis, 16 had stroke (2 -moyamoya cases), 18 had culture proven sepsis. Our population was further divided into 3 subgroups based on their age (Group 1 - 0-18 years; Group 2 - 19-40 years; group 3- above 40 years) and we found no statistical difference in the mean platelet volume across different age groups. However in pediatric population (Group 1), hydroxyurea was associated with significantly lower MPV, p=0.023 and this is independent of Hb F levels. Using linear regression model, with probability of death as a dependent variable and hydroxyurea, MPV as independent variables, MPV maintains a significant association with probability of death (p=0.003). We also found strong positive correlation of MPV with the probability of death in pediatric age group, p=0.004, r =0.405. Conclusion: MPV is an independent biomarker predicting disease severity and probability of death in patients with sickle cell disease with a strong correlation especially in pediatric age group. Although there was no statistical significance across age groups, the variation of MPV for each patient with age needs to be studied for better understanding. Hydroxyurea a known disease-ameliorating agent is associated with lower MPV values in pediatric age group. This effect is independent of the levels of fetal hemoglobin and may be due to anti-inflammatory effect of hydroxyurea or decreased platelet consumption. Figure. Figure. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document